Long-term survival trends of bladder cancer from 1972 to 2011 in Qidong

陈永胜; 陈建国; 朱　健

doi:10.19401/j.cnki.1007-3639.2016.09.002

您当前的位置：

首页 >

文章列表页 >

Long-term survival trends of bladder cancer from 1972 to 2011 in Qidong

更新时间：2025-12-31

- Long-term survival trends of bladder cancer from 1972 to 2011 in Qidong
- China Oncology Vol. 26, Issue 9, Pages: 727-734(2016)
- 作者机构：
  
  1. 启东肝癌防治研究所，启东人民医院,江苏,南通,226200
  2. 南通大学肿瘤医院研究所,江苏,南通,226361
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2016.09.002
  CLC：
- Published Online：26 October 2016，
  
  Published：26 October 2016
- 稿件说明：
移动端阅览
陈永胜,陈建国,朱　健,等. 启东市1972—2011年膀胱癌生存率长期趋势分析[J]. 中国癌症杂志, 2016, 26(9): 727-734.

陈永胜, 陈建国, 朱　健. Long-term survival trends of bladder cancer from 1972 to 2011 in Qidong[J]. China Oncology, 2016, 26(9): 727-734.
陈永胜,陈建国,朱　健,等. 启东市1972—2011年膀胱癌生存率长期趋势分析[J]. 中国癌症杂志, 2016, 26(9): 727-734. DOI： 10.19401/j.cnki.1007-3639.2016.09.002.

陈永胜, 陈建国, 朱　健. Long-term survival trends of bladder cancer from 1972 to 2011 in Qidong[J]. China Oncology, 2016, 26(9): 727-734. DOI： 10.19401/j.cnki.1007-3639.2016.09.002.

摘要

背景与目的：我国鲜见有以人群为基础的超过40年的膀胱癌生存率的报道。该研究对启东1972—2011年全人群膀胱癌登记病例进行生存率分析，为预后评价及防治提供依据。方法：1 619例登记病例的生存(死亡)情况随访截止于2012年4月。用SURV 3.01软件计算观察生存率(observed survival rate，OS)和相对生存率(relative survival rate，RS)。结果：膀胱癌1、3、5、10、15、20及30年OS分别为59.91%、43.49%、35.98%、26.91%、21.30%、18.37%及12.24%，1、3、5、10、15、20及30年RS分别为64.07%、53.02%、50.06%、52.42%、59.59%、76.39%及115.75%。其中男性1、3、5、10、15、20及30年OS分别为60.84%、43.91%、36.95%、27.31%、21.49%、18.29%及12.59%，1、3、5、10、15、20及30年RS分别为65.23%、53.95%、52.02%、54.57%、62.59%、79.12%及117.07%；女性1、3、5、10、15、20及30年OS分别为56.61%、42.03%、32.44%、25.65%、20.78%、18.80%及0%， 1、3、5、10、15、20及30年RS分别为59.99%、49.91%、43.37%、45.86%、51.21%、69.02%及0%，男性、女性生存率差异无统计学意义(P=0.256)。15~34岁、35~44岁、45~54岁、55~64岁、65~74岁及大于75岁各年龄组的5年RS分别为49.10%、67.53%、62.77%、53.92%、46.59%和39.85%；10年RS分别为49.79%、61.23%、52.99%、48.21%、54.94%和51.21%。20世纪80年代以来，膀胱癌5、10和15年RS均有上升趋势。结论：启东市全人群膀胱癌登记病例总体生存率在逐步提高，早期诊断和治疗方法的进步可能是膀胱癌生存率提高的影响因素。与发达国家相比，膀胱癌生存率的差距正在缩小，但仍有提高的空间。

Abstract

Background and purpose: There are few studies referring to population-based cancer survival of bladder cancer for more than forty years in China. This paper was to offer basis for assessing long-term survival trends of bladder cancer and the prognosis of this cancer through analysis of the survival rates based on cancer report documents from 1972 to 2011 in Qidong. Methods: The deadline of the last follow-up for survival status of the 1 619 registered cases was Apr. 2012. Cumulative observed survival rate (OS) and relative survival rate (RS) were calculated using Hakulinen’s method performed by the SURV3.01 Software which is developed by Finnish Cancer Registry. Results: The one-

three-

five-

ten-

fifteen-

twenty-

and thirty-year OS rates were 59.91%

43.49%

35.98%

26.91%

21.30%

18.37% and 12.24%; and the one-

three-

five-

ten-

fifteen-

twenty-

and thirty-year RS rates were 64.07%

53.02%

50.06%

52.42%

59.59%

76.39% and 115.75%

respectively. For males

these OS rates were 60.84%

43.91%

36.95%

27.31%

21.49%

18.29% and 12.59%

and RS rates were 65.23%

53.95%

52.02%

54.57%

62.59%

79.12% and 117.07%

respectively; For females

these OS rates were 56.61%

42.03%

32.44%

25.65%

20.78%

18.80% and 0%

and RS rates

59.99%

49.91%

43.37%

45.86%

51.21%

69.02% and 0%

respectively. There were no statistical differences could be found between both sexes (P=0.256). Five-year RS rates of age groups 15-34

35-44

45-54

55-64

65-74

and more than 75 were 49.10%

67.53%

62.77%

53.92%

46.59% and 39.85%

and 10-year RS rates

49.79%

61.23%

52.99%

48.21%

54.94% and 51.21%

respectively. Remarkable improvement could be seen for the five-

ten-

and fifteen-year RS rates in this setting since 1980’s. Conclusion: The survival outcome from Qidong registered cases with bladder cancer shows gradual progress during the past 2 decades. Early detection and improvement of therapies may be the factors affecting the prognosis of bladder cancer. Although the disparities in survival rates between Qidong and the developed countries are getting narrower

potential for survival improvement still exists.

关键词

Keywords

references

Views

1802

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expert consensus on early diagnosis and treatment of bladder cancer (2024 edition)

PRMT7 inhibits proliferation and migration of bladder cancer cells by regulating Notch signaling pathway

Advances in basic research, clinical diagnosis and treatment of bladder cancer in 2022

Analysis of current status of cervical cancer incidence and mortality in Shanghai, 2016 and trends of 2002-2016

A systematic review of current advancements of artificial intelligence in genitourinary cancers

Related Author

Oncology Group Urologic Chinese

Jiemin QI

Yu CHENG

Xuemei WANG

Shengfeng ZHENG

Yiping ZHU

Dingwei YE

Yi PANG

Related Institution

Department of Pathology, Chengde Medical University

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Municipal Center for Disease Control and Prevention

Division of Disease Control and Prevention Information, Shanghai Municipal Center for Disease Control and Prevention

Division of Noncommunicable Diseases and Injury, Shanghai Municipal Center for Disease Control and Prevention

AI问答

⁰